Anzeige
Mehr »
Login
Freitag, 25.04.2025 Börsentäglich über 12.000 News von 693 internationalen Medien
Vergiss die Indizes - Forge steigt um 40 %, während der S&P & Dow fällt!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14QXP | ISIN: FR0012127173 | Ticker-Symbol: 6OP
Tradegate
24.04.25
21:30 Uhr
5,855 Euro
+0,015
+0,26 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
OSE IMMUNOTHERAPEUTICS SA Chart 1 Jahr
5-Tage-Chart
OSE IMMUNOTHERAPEUTICS SA 5-Tage-Chart
RealtimeGeldBriefZeit
5,7755,79014:10
5,7705,78014:05

Aktuelle News zur OSE IMMUNOTHERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiOSE Immunotherapeutics Highlights Abstracts Selected for Presentation at ASCO 20251
09.04.OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 20252
03.04.OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 20252
OSE IMMUNOTHERAPEUTICS Aktie jetzt für 0€ handeln
03.04.OSE Immunotherapeutics - Primed for value appreciation276OSE Immunotherapeutics is a clinical-stage immuno-oncology and immuno-inflammation company, with a pipeline spanning all stages of development. The company recently reported its FY24 results, reflecting...
► Artikel lesen
26.03.OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update72OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update Total income of €83.4 million. Cash level of €64.2 million1 as of December 31, 2024, ensuring financial...
► Artikel lesen
12.03.OSE Immunotherapeutics - Tedopi shows promise in pancreatic cancer277OSE Immunotherapeutics has reported positive top-line data from the investigator-sponsored Phase II trial assessing Tedopi in combination with FOLFIRI (a three-drug chemotherapy regimen made up of folinic...
► Artikel lesen
11.03.OSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for Clinical Trial TEDOPaM Evaluating OSE2101 (Tedopi) in Advanced Pancreatic Cancer143OSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for Clinical Trial TEDOPaM Evaluating OSE2101 (Tedopi®) in Advanced Pancreatic Cancer Primary endpoint met in randomized...
► Artikel lesen
07.03.OSE Immunotherapeutics - KOL event highlights lusvertikimab's potential316OSE Immunotherapeutics and Edison held a key opinion leader (KOL) event on 5 March 2025, providing up-to-date insights into OSE's lead immuno-inflammation candidate, lusvertikimab, following the European...
► Artikel lesen
06.03.OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD2
24.02.OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO144OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO Lusvertikimab achieved statistical significance on...
► Artikel lesen
20.02.OSE Immunotherapeutics Presents Positive Preclinical Data on Combination of Anti-IL-7 Receptor Lusvertikimab in Chronic Colitis In Oral Presentation at 20th Congress of ECCO80OSE Immunotherapeutics Presents Positive Preclinical Data on Combination of Anti-IL-7 Receptor Lusvertikimab in Chronic ColitisIn Oral Presentation at 20th Congress of ECCO NANTES, France - February...
► Artikel lesen
29.01.OSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision Immunotherapy237OSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision Immunotherapy Nantes and Paris - France, January 29, 2025 - 6:00pm CET - OSE...
► Artikel lesen
28.01.OSE Immunotherapeutics Presents Three Abstracts for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO2
13.01.OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer342OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer NANTES, France, January 13, 2025 - 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today...
► Artikel lesen
18.12.24OSE Immunotherapeutics to Present Anti-IL-7R Lusvertikimab Phase 2 Induction Results in Ulcerative Colitis at 20th Congress of ECCO9
11.12.24OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi286OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi® ARTEMIA: Clinical trial protocol approved globally. Most countries and sites activated...
► Artikel lesen
02.12.24OSE Immunotherapeutics Strengthens Leadership and Executive Committee464OSE Immunotherapeutics Strengthens Leadership and Executive Committee NANTES, France, December 2, 2024 - 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced that...
► Artikel lesen
21.11.24OSE Immunotherapeutics - Full Lusvertikimab results reflect potential in UC351OSE Immunotherapeutics' final analysis of the CoTikiS trial in ulcerative colitis (UC) confirmed that Lusvertikimab met the primary endpoint with statistical significance, highlighting its potential...
► Artikel lesen
04.11.24OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis148OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis Lusvertikimab...
► Artikel lesen
09.10.24OSE Immunotherapeutics - Riding the H124 tailwinds389OSE Immunotherapeutics has reported its results for H124, a standout period for the company's development pipeline, with the momentum carrying into H224. The first half of the year rewarded the company...
► Artikel lesen
Seite:  Weiter >>
31 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1